Trial · NCT07906587
Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Study
NCT07906587, Phase 2, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Study. Trials, record NCT07906587. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07906587
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Study
- NCT number
- NCT07906587
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 86 participants, estimated
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Combining nimotuzumab and toripalimab with nab-paclitaxel plus cisplatin
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | MPR Major Pathological Response | 3 months | Proportion of patients with \<10% viable tumor cells in the resected primary tumor and regional lymph nodes after neoadjuvant treatment. |
| Secondary | Pathological Complete Response (pCR) rate | At the time of definitive surgery (postoperative pathological assessment), an expected average of 2.5 months after initiation of neoadjuvant therapy | Proportion of patients with no residual viable tumor cells in the resected primary tumor and regional lymph nodes (ypT0N0). |
| Secondary | Objective Response Rate (ORR) | After completion of 3 cycles of induction therapy (approximately 2.5 months after initiation of induction therapy) | Proportion of patients achieving complete response (CR) or partial response (PR) per RECIST 1.1. |
| Secondary | 2-year Event-Free Survival (EFS) rate | 2 years from treatment initiation | Proportion of patients free from events (recurrence, distant metastasis, second primary cancer, or death from any cause) at 2 years. |
| Secondary | 2-year Locoregional Control (LRC) rate | 2 years from treatment initiation | Proportion of patients without locoregional recurrence at 2 years. |
| Secondary | Safety and Tolerability | From first dose to 30 days after last treatment | Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) according to NCI-CTCAE 6.0. |
| Secondary | Prognostic biomarkers | Baseline (before initiation of treatment) and postoperative pathological assessment (approximately 3 months after initiation of treatment) | Exploratory analysis of baseline EGFR and PD-L1 expression and their association with prognosis. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07906587
GET https://conductscience.org/api/trials/v1/NCT07906587/registered